• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于药理学勃起程序的改良血管活性药物组合。

An improved vasoactive drug combination for a pharmacological erection program.

作者信息

Bennett A H, Carpenter A J, Barada J H

机构信息

Division of Urological Surgery, Albany Medical Center, New York.

出版信息

J Urol. 1991 Dec;146(6):1564-5. doi: 10.1016/s0022-5347(17)38167-3.

DOI:10.1016/s0022-5347(17)38167-3
PMID:1719248
Abstract

Papaverine hydrochloride (smooth muscle relaxant), phentolamine mesylate (alpha-adrenergic blocking agent) and prostaglandin E1 (vasodilator and smooth muscle relaxant) were combined to produce a potent vasoactive drug therapy for use in a pharmacological erection program. Doses of 2.5 cc papaverine (30 mg./cc), 0.5 cc phentolamine (5 mg./cc), 0.05 cc prostaglandin E1 (500 micrograms./cc) and 1.2 cc 0.9% normal saline were combined to produce a vial of 4.25 cc for patient convenience. Twenty unit vials were made from the 1 cc vial of prostaglandin E1, the most expensive ingredient. The solution is physiologically active for at least 6 months and can be stored at room temperature although refrigeration is recommended. The pH of the solution is 4. This vasoactive drug combination has been used in 116 patients for diagnostic testing and subsequent treatment. A dose of 0.25 cc has been effective for diagnosis and treatment in the majority of patients with mild to moderate arteriogenic and/or venogenic and diabetic impotence. For patients with neurogenic dysfunction 0.1 to 0.125 cc was the usual dose. Two patients had a prolonged erection requiring irrigation, 1 on the day of initial testing and 1 on home therapy. Pain at the site of injection or during intercourse was noted in only 2 patients and to date no fibrosis or plaques have been found.

摘要

盐酸罂粟碱(平滑肌松弛剂)、甲磺酸酚妥拉明(α-肾上腺素能阻滞剂)和前列腺素E1(血管扩张剂和平滑肌松弛剂)联合使用,产生一种强效血管活性药物疗法,用于药理学勃起方案。将2.5毫升罂粟碱(30毫克/毫升)、0.5毫升酚妥拉明(5毫克/毫升)、0.05毫升前列腺素E1(500微克/毫升)和1.2毫升0.9%生理盐水混合,制成4.25毫升的小瓶,方便患者使用。从1毫升前列腺素E1小瓶(最昂贵的成分)中制备了20个单位小瓶。该溶液至少6个月内具有生理活性,尽管建议冷藏,但可在室温下储存。溶液的pH值为4。这种血管活性药物组合已用于116例患者的诊断测试和后续治疗。0.25毫升的剂量对大多数轻度至中度动脉源性和/或静脉源性及糖尿病性阳痿患者的诊断和治疗有效。对于神经功能障碍患者,通常剂量为0.1至0.125毫升。两名患者出现持续性勃起需要冲洗,1例在初次测试当天,1例在家庭治疗期间。仅2例患者出现注射部位或性交时疼痛,迄今为止未发现纤维化或斑块。

相似文献

1
An improved vasoactive drug combination for a pharmacological erection program.一种用于药理学勃起程序的改良血管活性药物组合。
J Urol. 1991 Dec;146(6):1564-5. doi: 10.1016/s0022-5347(17)38167-3.
2
[Intracavernous injection of vasoactive drugs for treating erectile impotence].[海绵体内注射血管活性药物治疗勃起功能障碍]
Hinyokika Kiyo. 1988 Feb;34(2):301-4.
3
Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.海绵体内注射前列腺素E1与罂粟碱联合使用:与单独使用罂粟碱加酚妥拉明及单独使用前列腺素E1相比,效果更佳。
J Urol. 1991 Jan;145(1):56-9. doi: 10.1016/s0022-5347(17)38246-0.
4
Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.罂粟碱、酚妥拉明和前列腺素E1混合物与其他海绵体内注射剂的比较。
Eur Urol. 1994;26(4):319-21. doi: 10.1159/000475407.
5
[3 years' experience with intracavernous auto-injection therapy].[海绵体内自我注射疗法的3年经验]
Urologe A. 1989 Sep;28(5):253-6.
6
Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.前列腺素E1与酚妥拉明/罂粟碱治疗勃起功能障碍的双盲比较
J Urol. 1989 Mar;141(3):549-50. doi: 10.1016/s0022-5347(17)40889-5.
7
Experience with triple-drug therapy in a pharmacological erection program.
J Urol. 1993 Dec;150(6):1822-4. doi: 10.1016/s0022-5347(17)35905-0.
8
Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.罂粟碱加酚妥拉明与前列腺素E1治疗勃起功能障碍的对比研究
J Urol. 1997 Jun;157(6):2132-4.
9
[Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].[海绵体内注射血管活性药物治疗阳痿的临床评估:长期随访观察]
Hinyokika Kiyo. 1994 Jan;40(1):37-41.
10
Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.罂粟碱-酚妥拉明与前列腺素E1联合应用与单独应用罂粟碱-酚妥拉明用于体内注射治疗的临床双盲研究。
J Urol. 1995 Sep;154(3):1017-9.

引用本文的文献

1
Evaluation of the sensitivity of different doses of vasoactive drugs in diagnosing erectile dysfunction in impotent patients: a prospective case-control study.不同剂量血管活性药物诊断阳痿患者勃起功能障碍的敏感性评估:一项前瞻性病例对照研究。
Cent European J Urol. 2021;74(1):109-115. doi: 10.5173/ceju.2021.00042.R1. Epub 2021 Feb 6.
2
Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part II on Urological Management).前列腺放疗引起的性功能障碍:根治性放疗时代的综述及多学科管理指南(第二部分:泌尿外科管理)
Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):619-624. doi: 10.1016/j.rpor.2020.03.011. Epub 2020 May 6.
3
The Challenge of Erectile Dysfunction Management in the Young Man.
年轻男性勃起功能障碍管理面临的挑战。
Curr Urol Rep. 2015 Dec;16(12):84. doi: 10.1007/s11934-015-0553-3.
4
Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.韩国性医学和男科学会(KSSMA)勃起功能障碍指南。
World J Mens Health. 2013 Aug;31(2):83-102. doi: 10.5534/wjmh.2013.31.2.83. Epub 2013 Aug 31.
5
Future prospects in the treatment of erectile dysfunction: focus on avanafil.勃起功能障碍治疗的未来前景:聚焦于阿伐那非
Drug Des Devel Ther. 2011;5:435-43. doi: 10.2147/DDDT.S15852. Epub 2011 Oct 18.
6
Looking to the future for erectile dysfunction therapies.展望勃起功能障碍治疗的未来。
Drugs. 2008;68(2):231-50. doi: 10.2165/00003495-200868020-00006.
7
Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.心血管疾病患者男性勃起功能障碍和女性性功能障碍的病因及管理
Drugs Aging. 2005;22(10):823-44. doi: 10.2165/00002512-200522100-00003.
8
A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?勃起功能障碍治疗方案的比较性综述:何种治疗适用于何种患者?
Drugs. 2005;65(12):1621-50. doi: 10.2165/00003495-200565120-00003.
9
Intracavernous pharmacotherapy for erectile dysfunction.阴茎海绵体内药物治疗勃起功能障碍。
Endocrine. 2004 Mar-Apr;23(2-3):149-55. doi: 10.1385/ENDO:23:2-3:149.
10
Erectile dysfunction: management update.勃起功能障碍:管理更新
CMAJ. 2004 Apr 27;170(9):1429-37. doi: 10.1503/cmaj.1020049.